Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma

Leukemia & Lymphoma
J LiliemarkG Juliusson

Abstract

Thirty-six patients with previously treated low-grade non-Hodgkin's lymphoma (LG-NHL) were included in a phase II study between August 1990 and February 1994 and treated with 0.12 mg/kg CdA as a 2 h.i.v. infusion daily x V, q 28 days up to 6 courses. Twenty-three were refractory to previous chemotherapy while 13 were relapsed. Four patients had mantle cell lymphoma, 17 follicle centre cell derived lymphoma, 7 lymphoplasmacytoid lymphomas and, 8 had small lymphocytic lymphoma. The response rate was 42%, with 5 (14%) CR and 10 (28%) PR while 6 (16%) patients progressed during treatment. The median number of delivered CdA courses was 3 (1-6) in non-responding cases and 6 (2-6) in responders. The median time to progression was 9 mo for all patients, 23 mo for CR and 16 mo for PR patients. Toxicity was sometimes severe with 3 infectious deaths (1 pneumocystis carinii pneumonia, 1 gram negative septicemia, and 1 fungal pneumonia), and 6 grade 3 or 4 infectious episodes. We conclude that responses to CdA in this group of heavily pre-treated patients is impressive. However, toxicity is considerable and the rate of opportunistic infections is worrisome.

References

Mar 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V M SantanaR L Blakley
Mar 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C KayL D Piro
Oct 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J LiliemarkG Juliusson
Apr 19, 1990·The New England Journal of Medicine·L D PiroE Beutler
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D Cheson
Apr 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G JuliussonG Tjønnfjord
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL D Piro
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Juliusson, J Liliemark
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G JuliussonJ Liliemark

❮ Previous
Next ❯

Citations

Aug 26, 1998·Leukemia & Lymphoma·J LiliemarkG Juliusson
Jul 24, 2014·Clinical Lymphoma, Myeloma & Leukemia·Annete NjueFarrukh Awan
Apr 12, 2008·Expert Review of Anticancer Therapy·Darren S Sigal, Alan Saven
Nov 13, 2009·Journal of Clinical and Experimental Hematopathology : JCEH·Yasushi TakamatsuKazuo Tamura
Dec 7, 2002·Best Practice & Research. Clinical Haematology·Pier Luigi Zinzani

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.